Laing Jennifer M, Aurelian Laure
Department of Pharmacology and Experimental Therapeutics, University of Maryland, School of Medicine, Baltimore, MD 21201, USA.
Genet Vaccines Ther. 2008 Jan 7;6:1. doi: 10.1186/1479-0556-6-1.
Ischemic brain injury and epilepsy are common neurodegenerative diseases caused by excitotoxicity. Their pathogenesis includes microglial production of inflammatory cytokines. Our studies were designed to examine whether a growth compromised HSV-2 mutant (Delta RR) prevents excitotoxic injury through modulation of microglial responses by the anti-apoptotic HSV-2 protein ICP10PK. EOC2 and EOC20 microglial cells, which are differentially activated, were infected with Delta RR or the ICP10PK deleted virus (Delta PK) and examined for virus-induced neuroprotective activity. Both cell lines were non-permissive for virus growth, but expressed ICP10PK (Delta RR) or the PK deleted ICP10 protein p95 (Delta PK). Conditioned medium (CM) from Delta RR-, but not Delta PK-infected cells prevented N-methyl-D-aspartate (NMDA)-induced apoptosis of primary hippocampal cultures, as determined by TUNEL and caspase-3 activation (76.9 +/- 5.3% neuroprotection). Neuroprotection was associated with inhibition of TNF-alpha and RANTES and production of IL-10. The CM from Delta PK-infected EOC2 and EOC20 cells did not contain IL-10, but it contained TNF-alpha and RANTES. IL-10 neutralization significantly (p < 0.01) decreased, but did not abrogate, the neuroprotective activity of the CM from Delta RR-infected microglial cultures indicating that ICP10PK modulates the neuronal-microglial axis, also through induction of various microglial neuroprotective factors. Rats given Delta RR (but not Delta PK) by intranasal inoculation were protected from kainic acid (KA)-induced seizures and neuronal loss in the CA1 hippocampal fields. Protection was associated with a significant (p < 0.001) increase in the numbers of IL-10+ microglia (CD11b+) as compared to Delta PK-treated animals. Delta RR is a promising vaccination/therapy platform for neurodegeneration through its pro-survival functions in neurons as well as microglia modulation.
缺血性脑损伤和癫痫是由兴奋性毒性引起的常见神经退行性疾病。它们的发病机制包括小胶质细胞产生炎性细胞因子。我们的研究旨在检验生长受限的单纯疱疹病毒2型(HSV-2)突变体(Delta RR)是否通过抗凋亡的HSV-2蛋白ICP10PK调节小胶质细胞反应来预防兴奋性毒性损伤。分别用Delta RR或缺失ICP10PK的病毒(Delta PK)感染差异激活的EOC2和EOC20小胶质细胞,并检测病毒诱导的神经保护活性。两种细胞系均不允许病毒生长,但表达ICP10PK(Delta RR)或缺失PK的ICP10蛋白p95(Delta PK)。通过TUNEL和半胱天冬酶-3激活测定,来自Delta RR感染而非Delta PK感染细胞的条件培养基(CM)可预防原代海马培养物中N-甲基-D-天冬氨酸(NMDA)诱导的凋亡(神经保护率为76.9±5.3%)。神经保护与肿瘤坏死因子-α(TNF-α)和调节激活正常T细胞表达和分泌因子(RANTES)的抑制以及白细胞介素-10(IL-10)的产生有关。来自Delta PK感染的EOC2和EOC20细胞的CM不含IL-10,但含有TNF-α和RANTES。IL-10中和显著(p<0.01)降低但未消除来自Delta RR感染的小胶质细胞培养物CM的神经保护活性,表明ICP10PK也通过诱导各种小胶质细胞神经保护因子调节神经元-小胶质细胞轴。经鼻接种Delta RR(而非Delta PK)的大鼠可免受海藻酸(KA)诱导的癫痫发作和海马CA1区神经元丢失。与Delta PK处理的动物相比,保护与IL-10+小胶质细胞(CD11b+)数量显著(p<0.001)增加有关。Delta RR通过其在神经元中的促存活功能以及小胶质细胞调节,是一种有前景的神经退行性疾病疫苗接种/治疗平台。